LENSKARTLenskart Solutions Limited
Convert to ideaHealthcare · Medical Equipment
The verdict combines business quality, price and timing. Sign in free to see it.
Sign in freeUp 0.8 this quarter.
Momentum from moving averages, Supertrend and RSI.
1 forensic issue found. Sign in to see which.
Valuation Metrics
Q2 FY2027Intrinsic value, Graham number and DCF against today's price
1 found · risk minor
Quality, growth, balance sheet and earnings quality behind the score
ⓘ Based on fundamental & forensic analysis. Always verify against official filings and consult a financial advisor.
Financial Metrics
Comparing Q2 FY2027 vs Q2 FY2026
| Quarter | Revenue | Net Profit | OPM | NPM | EPS | Int. Cover |
|---|---|---|---|---|---|---|
| Q2 FY2027 | ₹2845 Cr | ₹232 Cr | 10.59% | 8.17% | ₹1.31 | 6.7x |
| Q1 FY2027 | ₹2714 Cr | ₹228 Cr | 10.46% | 8.42% | ₹1.28 | 6.6x |
| Q4 FY2026 | ₹2516 Cr | ₹204 Cr | 9.97% | 8.09% | ₹1.17 | 6.9x |
| Q3 FY2026 | ₹2308 Cr | ₹133 Cr | 8.40% | 5.75% | ₹0.77 | 4.7x |
| Q2 FY2026 | ₹1229 Cr | ₹99 Cr | 10.11% | 8.06% | ₹0.59 | 5.4x |
Momentum score, 1-year chart, moving averages, support and resistance.
Turnaround stage, and how each measure moved over 3 years against the company's own range.
Order wins, capex, pledges, rating actions and every material filing.
Management guidance, Q&A highlights and whether they delivered what they said.
The earnings call read across investor dimensions.
Promoter, FII and mutual fund holding, and what changed this quarter.
Similar-size peers in Medical Equipment
Compare with peers →Note: This comprehensive analysis combines technical data, fundamental data, and investment thesis. Always do your own research and consider your personal risk tolerance before investing.